Sanofi gets first ever approval within Niemann-Pick as Japan green-lights drug

As the first country in the world, Japan has approved a treatment, Sanofi-developed Xenpozyme, for Niemann-Pick disease type A, also known as acid sphingomyelinase deficiency (ASMD).

Photo: Benoit Tessier/Reuters/Ritzau Scanpix

Sanofi is the first and only company in the world to receive an approval for a drug targeting the disease acid sphingomyelinase deficiency (ASMD), Sanofi reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs